Proliferative lupus nephritis treatment: Practice survey in nephrology and internal medicine in France;Prise en charge des glomérulonéphrites lupiques prolifératives: enquête de pratique du Groupe coopératif sur le lupus rénal auprès des néphrologues et internistes français

Nephrologie et Therapeutique

Volumn 10, Issue 3, 2014, Pages 170-176

  Jourde Chiche, Noémie ^a   Chiche, Laurent ^a   Mancini, Julien ^a   Daniel, Laurent ^a   Bardin, Nathalie ^b   Burtey, Stéphane ^a   Gondouin, Bertrand ^a   Dussol, Bertrand ^a   Harlé, Jean Robert ^a   Hamidou, Mohamed ^c   Meulders, Quentin ^d   Daugas, Éric ^e  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c HÔTEL DIEU   (France)

^d CENTRE HOSPITALIER D AVIGNON   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

Induction treatment lupus nephritis; Maintenance treatment; Survey

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ARTICLE; CORTICOSTEROID THERAPY; DRUG MEGADOSE; FRANCE; HEALTH SURVEY; HOSPITAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNIST; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEDICAL SPECIALIST; NEPHROLOGIST; PRESCRIPTION; PROLIFERATIVE LUPUS NEPHRITIS; REMISSION; RHEUMATOLOGY; SOCIETY; ANALOGS AND DERIVATIVES; CLINICAL PRACTICE; INTERNAL MEDICINE; LUPUS NEPHRITIS; NEPHROLOGY; QUESTIONNAIRE;

AZATHIOPRINE; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNAL MEDICINE; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; NEPHROLOGY; PRACTICE PATTERNS, PHYSICIANS'; SURVEYS AND QUESTIONNAIRES;

EID: 84901810364     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2013.11.006     Document Type: Article

References (13)

1. R. Cervera, M.A. Khamashta, J. Font, G.D. Sebastiani, A. Gil, and P. Lavilla et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients Medicine (Baltimore) 82 5 2003 299 308
2. H.M. Bastian, J.M. Roseman, G. McGwin Jr., G.S. Alarcón, A.W. Friedman, and B.J. Fessler et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus in minority populations: nature vs nurture Lupus 11 3 2002 152 160
3. F.A. Houssiau, C. Vasconcelos, D. D'Cruz, G.D. Sebastiani, E. de Ramon Garrido, and M.G. Danieli et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide Ann Rheum Dis 69 1 2010 61 64
4. J.J. Weening, V.D. D'Agati, M.M. Schwartz, S.V. Seshan, C.E. Alpers, and G.B. Appel et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited Kidney Int 65 2004 521 530
5. B.H. Hahn, M.A. McMahon, A. Wilkinson, W.D. Wallace, D.I. Daikh, and J.D. Fitzgerald et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Arthritis Care Res (Hoboken) 64 6 2012 797 808
6. G.K. Bertsias, M. Tektonidou, Z. Amoura, M. Aringer, I. Bajema, and J.H.M. Berden et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis Ann Rheum Dis 71 11 2012 1771 1782
7. Kidney Disease - Improving Global Outcomes (KDIGO). KDIGO Clinical practice Guideline for Glomerulonephritis. www.kdigo.org/clinical-practice- guidelines/pdf/KDIG-GN-Guideline.pdf
8. B.H. Rovin, R. Furie, K. Latinis, R.J. Looney, F.C. Fervenza, and J. Sanchez-Guerrero et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study Arthritis Rheum 64 4 2012 1215 1226
9. M. Weidenbusch, C. Römmele, A. Schröttle, and H.J. Anders Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis Nephrol Dial Transplant 28 1 2013 106 111
10. M.B. Condon, D. Ashby, R.J. Pepper, H.T. Cook, J.B. Levy, and M. Griffith et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids Ann Rheum Dis 72 8 2013 1280 1286
11. F.A. Houssiau, D. D'Cruz, S. Sangle, P. Remy, C. Vasconcelos, and R. Petrovic et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial Ann Rheum Dis 69 2010 2083 2089
12. M.A. Dooley, D. Jayne, E.M. Ginzler, D. Isenberg, N.J. Olsen, and D. Wofsy et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis N Engl J Med 365 2011 1886 1895
13. K. Laskari, A.G. Tzioufas, A. Antoniou, and H.M. Moutsopoulos Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis J Rheumatol 38 7 2011 1304 1308